Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670525 · ClinicalTrials.gov registry record · NA
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
A NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 338
- Enrollment target
- 15
- Study locations
NCT02670525 is a NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 338 participants. The trial reports 15 study locations across 12 states.
The verdict
NCT02670525, a NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 338 participants
- Enrollment target
- 15
- Study locations
Study Summary
This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.
Conditions Studied
Interventions
- GENETIC Leukemia Profiling
Study Locations (15)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- The Children's Hospital at Montefiore - The Bronx
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- The University of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Children's Hospital's and Clinics of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670525
The ClinicalTrials.gov registry entry for NCT02670525 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent, Refractory, or High Risk Leukemias appearing as the primary indexed condition, and to 1 intervention - of which Leukemia Profiling is the first listed.
NCT02670525 reports 15 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02670525 about?
NCT02670525 is a clinical study titled "Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome". This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of ...
What is the current status of trial NCT02670525?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 338 participants. The study started on 2016-08-17. Estimated completion is 2028-01-31.
What conditions does trial NCT02670525 study?
This clinical trial studies the following conditions: Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy.
What interventions are being tested in trial NCT02670525?
The interventions under investigation include: Leukemia Profiling (GENETIC).
Who is sponsoring clinical trial NCT02670525?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02670525 being conducted?
This trial has 15 study locations across California, Colorado, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Recurrent, Refractory, or High Risk Leukemias
All registered trials for this condition
Matched Targeted Therapy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.